Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Leadhexa Biotechnologies

Leadhexa Biotechnologies
Out of Business LATEST DEAL TYPE

Developer of molecular technology designed to discovered enzyme Manganese Superoxide Dismutase. The company's technology demonstrated efficacy in numerous preclinical models including actinic keratosis, radiation protection, protection of kidney damage due to cyclosporine, liver cirrhosis and liver ischemia-reperfusion injury, enabling doctors to remove supra-stoichiometric amounts of reactive oxygen species to enter in the Mitochondria and cells.

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Primary Office
  • 953 Indiana Street
  • San Francisco, CA
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Leadhexa Biotechnologies’s full profile, request a free trial.

Leadhexa Biotechnologies Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Jan-2015 Completed Out of Business
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Leadhexa Biotechnologies Executive Team (3)

Name Title Board
Aldo Mancini Co-Founder, Chief Executive Officer & President
Francesco Ambesi-Impiombato Co-Founder
Roberto Mancini MD Researcher